Research progress of tumor immunotherapy-associated optic nerve adverse events, prevention and treatment
10.3760/cma.j.cn511434-20221216-00663
- VernacularTitle:肿瘤免疫治疗相关的视神经不良反应及其防治的研究进展
- Author:
Luyin ZHANG
1
;
Libin JIANG
Author Information
1. 首都医科大学附属北京同仁医院 北京同仁眼科中心, 北京 100730
- Keywords:
Immunotherapy;
Immune checkpoint inhibitors;
Immune-related adverse events;
Optic neuropathy;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(10):857-861
- CountryChina
- Language:Chinese
-
Abstract:
Tumor immunotherapy includes immune checkpoint inhibitor (ICI), tumor vaccines, and adoptive cell therapy. Immunotherapy, as the main systemic treatment for advanced malignant tumors, kills tumor cells by activating the immune system and prolongs the survival of patients. However, excessive immune responses can cause immune-related adverse events (irAE), causing damage to systemic tissues. ICI are the main tumor immunotherapy drugs that cause optic nerve irAE. The most common optic nerve irAE are optic neuritis, only a few patients appeared arteritic anterior ischemic optic neuropathy. Sudden painless loss of bilateral vision is the most common clinical manifestation. In severe cases, the vision decrease to no light perception. Early diagnosis and early adequate glucocorticoid treatment can improve the symptoms. Therefore, neuro-ophthalmologists and oncologists should know the clinical characteristics of optic nerve irAE, in order to diagnose and treat early and improve the prognosis.
